Clinica Chimica Acta, Journal Year: 2025, Volume and Issue: unknown, P. 120385 - 120385
Published: May 1, 2025
Language: Английский
Aging and Disease, Journal Year: 2025, Volume and Issue: unknown, P. 0 - 0
Published: Jan. 1, 2025
Nanozymes, which are nanomaterials that replicate the catalytic activities of natural enzymes in biological systems, have recently demonstrated considerable potential improving cancer immunotherapy by altering tumor microenvironment. Nanozyme-driven immune responses represent an innovative therapeutic modality with high effectiveness and minimal side effects. These nanozymes activate system to specifically recognize destroy cells. Combined immunotherapeutic agents, can amplify anti-cancer integrating remodeling immunogenic cell death (ICD). This review offers a thorough discussion about various involved immunity, including those mimicking catalase (CAT), superoxide dismutase (SOD), peroxidase (POD), oxidase (OXD). It also discusses challenges future directions for translating nanozyme platforms into clinical applications, enhancing susceptibility cells immunotherapy. Nanozyme-based strategies substantial oncology, offering new effective options management.
Language: Английский
Citations
0
Mechanisms of Ageing and Development, Journal Year: 2025, Volume and Issue: 225, P. 112045 - 112045
Published: March 11, 2025
Cancer remains one of the most devastating diseases, severely affecting public health and contributing to economic instability. Researchers worldwide are dedicated developing effective therapeutics target cancer cells. One promising strategy involves inducing cellular senescence, a complex state in which cells exit cell cycle. Senescence has profound effects on both physiological pathological processes, influencing systems through secreted factors that affect surrounding distant Among these exosomes, small extracellular vesicles play crucial roles communication, development, defense, can contribute conditions. Recently, there been increasing interest engineering exosomes as precise drug delivery vehicles, capable targeting specific or intracellular components. Studies have emphasized significant role from senescent progression therapy. Notably, chemotherapeutic agents alter tumor microenvironment, induce trigger immune responses exosome-mediated cargo transfer. This review explores intricate relationship between cancer, examining how different eliminate promote resistance. It also investigates molecular mechanisms signaling pathways driving highlighting current challenges proposing future perspectives uncover new therapeutic strategies for treatment.
Language: Английский
Citations
0
Journal of Nanobiotechnology, Journal Year: 2025, Volume and Issue: 23(1)
Published: March 20, 2025
Sjögren's syndrome (SS) is an autoimmune disease primarily affecting salivary glands, with xerostomia as a distinct clinical manifestation. This also poses significantly increased risk of lymphoma, severely impacting patients' quality life. The imbalance between Th17 and Treg cells plays critical role in SS progression, driving severe immune dysregulation, chronic inflammation, escalating tissue dysfunction. However, current treatments for still remain limited, it continues to be recognized refractory disease. Therefore, the development novel effective therapeutic strategies pressing demand research. In recent years, extracellular vesicle (EV) therapy has emerged promising approach treatment, showing encouraging outcomes modulating balance alleviating symptoms. EVs carry diverse cargo, among which microRNAs (miRNAs) are highly abundant play roles. These small RNAs essential EV-mediated functions, particularly regulating gene expression microenvironment. Our research team first isolated labial gland mesenchymal stem (LGMSCs) their derived (LGMSC-EVs), offer potential advantages due origin. Then we screened identified enriched miRNA let-7f-5p key regulator through profiling analysis. To achieve better outcomes, transfected exogenous into LGMSC-EVs upregulate its expression, thereby constructing let-7f-5p-encapsulated LGMSC-EVs. modified were subsequently tested experimental mouse model evaluate potential. upregulation enhanced effects, resulting improvements such flow reduced lymphocytic infiltration. Mechanistically, suppressed by directly targeting 3'-untranslated region (3'UTR) RORC, inhibiting RORC/IL-17A signaling axis, reducing IL-17A production, restoring Th17/Treg promoting anti-inflammatory profile. Collectively, this LGMSC-EV offers target-driven treatment SS, achieving improved rebalance after modification let-7f-5p, presents new SS.
Language: Английский
Citations
0
Cellular Signalling, Journal Year: 2025, Volume and Issue: unknown, P. 111758 - 111758
Published: March 1, 2025
Language: Английский
Citations
0
Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15
Published: March 25, 2025
Background Lung adenocarcinoma (LUAD) is the primary subtype of Non-small cell lung cancer (NSCLC) and a serious threat to human health. However, precise molecular mechanisms in remain largely unexplored. Methods Herein, we performed proteomic analysis cohort 20 LC tumors their paired normal tissues. The expression levels prognostic value hub proteins were also explored LUAD using public databases. Glycinamide ribonucleotide transformylase (GART) was detected by qRT-PCR lines. roles GART assessed CCK-8, colony formation, Wound healing assays, xenograft tumor model. Expression PAICS-Akt-β-catenin pathway estimated through western blot assays. Results tissues indicated that 263 upregulated 194 downregulated. Bioinformatics showed differentially expressed mainly associated with regulation apoptotic process adhesion, PI3K-Akt signaling pathway, Purine metabolism, Wnt pathway. EPRS, GART, HSPE1, RPS6 much higher than analyzed Ualcan database. Overexpression represented poor prognosis patients. Additionally, knockdown effectively inhibited proliferation migration cells both vitro vivo. Mechanistically, analyses suggested deletion could inhibit activation vivo . Conclusions Our study tumor-promoting function axis, it may be used as therapeutic target for NSCLC.
Language: Английский
Citations
0
International Immunopharmacology, Journal Year: 2025, Volume and Issue: 155, P. 114653 - 114653
Published: April 14, 2025
Language: Английский
Citations
0
Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 116928 - 116928
Published: April 1, 2025
Language: Английский
Citations
0
Clinica Chimica Acta, Journal Year: 2025, Volume and Issue: unknown, P. 120385 - 120385
Published: May 1, 2025
Language: Английский
Citations
0